6505--Clonidine Patches

The Department of Veterans Affairs National Acquisition Center is seeking a contractor to supply Clonidine transdermal patches in three strengths (0.1mg, 0.2mg, and 0.3mg) through VA and Department of Defense Pharmaceutical Prime Vendor Programs. The solicitation, identified as 36E79725R0037, requires offerors to submit pricing for a base year and four one-year option periods, with an anticipated single aggregate award. Contractors must provide pricing that includes a 0.5% Cost Recovery Fee and submit a unique 11-digit National Drug Code (NDC) number with their proposal. The evaluation will be conducted on a lowest-price technically acceptable basis, with key assessment factors including FDA approval, manufacturing facility compliance, and product specifications. Proposals must be submitted electronically by email to specified VA contacts by June 10, 2025, at 2:30 PM Central Time.

The procurement is set aside for small businesses with a size standard of 1,300 employees, targeting pharmaceutical manufacturers in the NAICS 325412 category. The estimated annual requirements range from 28,788 to 36,204 boxes of Clonidine patches, which will be distributed across various federal agencies including VA medical facilities, Department of Defense, Indian Health Service, and Bureau of Prisons. While specific incumbent contractor information is not provided, the solicitation indicates a comprehensive approach to meeting pharmaceutical needs across multiple federal healthcare systems. The contract will support multiple federal healthcare providers, with the primary performance location likely being the VA National Acquisition Center in Hines, Illinois. The procurement represents a strategic approach to ensuring consistent and cost-effective access to critical pharmaceutical products for federal healthcare institutions.